doi: https://onlinelibrary.wiley.com/doi/full/10.1111/cge.12930<br><br><br <span style="color:red" title="HPO: HP:0001510
CONF: 1" >>biallelic iars mutations in a child with intrauterine growth retarda</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >tion,</span>  neonatal cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >,</span>  and mild developmental delay - orenstein - 2017 - clinical genetics - wiley onli <span style="color:red" title="HPO: HP:0001263
CONF: 1" >ne library<br>working off-campus? learn about our<br>by continuing to browse </span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >this site,</span>  you agree to its use of cookies as described in our .<br>access byutrecht university<br>access byutrecht university<br>< <span style="color:red" title="HPO: HP:0001510
CONF: 1" >h5><br>search within<br>short report<br>full access<br><h1>biallelic mutations in a child with intrauterine growth retard</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >ation,</span>  neonatal cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >,</span>  and mild developmental delay <span style="color:red" title="HPO: HP:0001263
CONF: 1" ><br></h1><br>first publis</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >hed:</span>  28 november 2016<br>citations:<br><h5><br>all contributors have read and approved the submission to the journal. we are not aware of any conflict of interest.<br>give access<br><h5>share full-text access<br>please review our and check box below to share full-text version of article. i have read and accept the wiley online library terms and conditions of useshareable linkuse the link below to share a full-text version of this article with your friends and colleagues. <br>copy url<br>share a link<br>share on<br><h2>abstract</h2><br><br>recently, biallelic mutations in cytosolic isoleucyltrna synthetase () have been described in three individuals with growth de <span style="color:red" title="HPO: HP:0001510
CONF: 1" >lay,</span>  hepatic dysfunction, and neurodevelopmental disabilities. here we report an additional subject with this condition identified by wholeexome sequencing. our findings support the association between this disorder and neonatal cholestasis with distinct liver pathology <span style="color:red" title="HPO: HP:0001396
CONF: 1" >.</span>  furthermore, we provide functional data on two novel missense substitutions and expand the phenotype to incl <span style="color:red" title="HPO: HP:0001263
CONF: 1" >ude mild developmental delay</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >,</span>  skin hyperelasticity <span style="color:red" title="HPO: HP:0000974
CONF: 1" >,</span>  and hypervitaminosis d.<br>aminoacyltrna synthetases (arss) are ubiquitously expressed, highly conserved enzymes involved in attaching the appropriate amino acid to trna to enable protein synthesis . all arss contain catalytic and anticodon recognition domains to catalyze the aminoacylation reactions specific for their cognate amino acids . some arss harbor noncanonical domains with various activities including regulation of gene transcription and expression. in the past decade mutations in a growing number of arss were linked to human disease , . four human cytosolic arss have been implicated in autosomal dominant charcotmarietooth disease <span style="color:red" title="HPO: HP:0000006
CONF: 1" > ,</span>  - and mutations in mitochondrial arss cause a spectrum of mitochondrial disorders <span style="color:red" title="HPO: HP:0001427
CONF: 1" > .</span>  recently, kopajtich et al. reported three individuals harboring biallelic mutations in cytosolic isoleucyltrna synthetase () (mim: 600709). these individuals had a di <span style="color:red" title="HPO: HP:0001510
CONF: 1" >stinct syndrome of prenata</span>  <span style="color:red" title="HPO: HP:0001511
CONF: 1" >l onset growth retardation</span>  <span style="color:red" title="HPO: HP:0003577
CONF: 1" >,</span>  intellectual disability <span style="color:red" title="HPO: HP:0001249
CONF: 1" >,</span>  and liver dysfunction <span style="color:red" title="HPO: HP:0001410
CONF: 1" > .</span>  here, we report an additional subject with biallelic missense substitutions in and overlapping clinical findings. this report confirms the association with neonatal cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >,</span>  expands the related phenotype and provides functional data on two pathogenic variants detected in a family of arab descent.<br><h2> materials and methods</h2><br><br><h3> genetic testing</h3><br>the family consented for whole exome sequencing, biological assays and publication of photos according to our irb approved protocol (: nct01294345). whole exome sequencing was performed at the nih intramural sequencing center (nisc) using the seqcap ez exome version 3.0 capture kit (roche nimblegen, madison wi) and the illumina hiseq2500 platform. sequencing data were aligned to the human reference genome using novoalign (novocraft technologies, petaling jaya, malaysia). variants were called using the in house mpg genotype caller. detected variants were annotated and filtered using phenodb (baylorhopkins center for mendelian genomics) .<br><h3> yeast complementation assays</h3><br>to evaluate the functional consequence of the variants identified in the patient described here we performed yeast complementation assays utilizing a pyy1 expression construct. similar studies have successfully revealed the functional consequences of many diseaseassociated aminoacyltrna synthetase mutations and were recently employed to study the functional consequences of other variants . here, the endogenous yeast gene is deleted and the ability of wildtype and mutant human alleles to support yeast cell growth is used as a proxy for enzyme function. detailed methods are described in the appendix s1 (supporting information).<br><h2> results</h2><br><br><h3> case description</h3><br>the proband is the third son of nonconsanguineous parents of arab descent. the pregnancy was complicated by abnormal first trimester screening with 1:35 risk for down syndrome due to increased hcg. anatomic ultrasound at 18 weeks was normal, but at 24 weeks decreased growth was noted. during the third trimester there was growth delay and <span style="color:red" title="HPO: HP:0001510
CONF: 1" ></span>  oligohydramnios <span style="color:red" title="HPO: HP:0001562
CONF: 1" >.</span>  he was delivered via spontaneous vaginal delivery at 37 weeks gestation. the birth weight was 1840 g (=2.52) and the head circumference (hc) was 29.7cm (=2.6). the apgar scores were 9 and 10 at 1 and 5 min, respectively. he was admitted to the nic <span style="color:red" title="HPO: HP:0001518
CONF: 1" >u for low birth weight and</span>  <span style="color:red" title="HPO: HP:0004325
CONF: 1" ></span>  hypoglycemia (27mg/dl) that resolved with feedi <span style="color:red" title="HPO: HP:0001943
CONF: 1" >ng.</span>  during his admission he developed dir <span style="color:red" title="HPO: HP:0002904
CONF: 1" >ect hyperbilirubinemia up to 7.5mg/dl</span>  <span style="color:red" title="HPO: HP:0002908
CONF: 1" >,</span>  increased alkaline phosphatase 1450 (u/l) a <span style="color:red" title="HPO: HP:0003155
CONF: 1" >nd</span>  ggt 311 (u/l). he had abnormal live <span style="color:red" title="HPO: HP:0001392
CONF: 1" >r enzymes got 200 (u/</span>  <span style="color:red" title="HPO: HP:0002910
CONF: 1" >l),</span>  gpt 108 (u/l), hypoalbuminemia and <span style="color:red" title="HPO: HP:0003073
CONF: 1" ></span>  hyperammonemia (13 <span style="color:red" title="HPO: HP:0001987
CONF: 1" >9).</span>  he was treated with vitamin k and fresh frozen plasma because his blood did not clot and inr was not measurable, with improvement in the inr (1.5) that later on normalized. treatment with ursodeoxycholic acid was initiated and he received pregestimil per nasogastric (ng) tube. he had a normal echocardiogram. on abdominal us the liver was normal in size and texture. there was a duplicated collecting system on the left and <span style="color:red" title="HPO: HP:0000081
CONF: 1" ></span>  mild bilateral <span style="color:red" title="HPO: HP:0000126
CONF: 1" > hydronephrosis</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >.</span>  a hida scan was normal with no evidence of obstruction. a core needle biopsy of the liver was performed at the age of 1 month (fig. a). the lobular architecture was preserved, with bile stasis in hepatocytes. fibrosis with new vessel formation was seen in portal spaces <span style="color:red" title="HPO: HP:0006580
CONF: 1" >.</span>  no bile duct was traced in eight portal spaces. bile ductular proliferation was seen and demonstrated by immunostain for cytokeratin (ck). gradually the jaundice resolved and <span style="color:red" title="HPO: HP:0000952
CONF: 1" ></span>  the liver enzymes normalized. he had increased levels of 25hydroxy vitamin d (up to 253nmol/l) with normal pth levels of unknown cause. he received routine supplements until 12 months of age (400 units daily). after discontinuation of supplements, levels decreased to the high normal range (fig. s1). repeated zinc levels were within normal range. during his nicu admission there was one episode of urinary tract infection with <span style="color:red" title="HPO: HP:0000010
CONF: 1" > ..</span>  at 1 year, his length, weight and hc measured at 5 sd. on examination he had abnormal f <span style="color:red" title="HPO: HP:0000271
CONF: 1" >at distribution with a round face</span>  <span style="color:red" title="HPO: HP:0000311
CONF: 1" >,</span>  full cheeks and <span style="color:red" title="HPO: HP:0000293
CONF: 1" ></span>  increased fat in the genitalia area. he had joint hyperlaxity and <span style="color:red" title="HPO: HP:0001388
CONF: 1" ></span>  his skin was hyperelastic <span style="color:red" title="HPO: HP:0000974
CONF: 1" >,</span>  doughy like and transparent (fig. b). he received formula supplements via ng tube until the age of 4 years. he is treated with growth hormone (gh) since the age of 19 months for gh resistance (abnormal igf1 generation t <span style="color:red" title="HPO: HP:0001507
CONF: 1" >est),</span>  potentially secondary to his liver dysfunction and <span style="color:red" title="HPO: HP:0001410
CONF: 1" ></span>  poor nutrition status. at the age of 4 years the height and length were within normal range (0.5 sd) and the hc was at 2.5 sd. in terms of his development he walked at 18 months and his first words were at 18 months. currently he attends a regular preschool but a neuropsychological evaluation demonstrated a 45 months delay on the cognitive adaptive test/clinical linguistic and auditory milestone scale (cat clams) and he is now receiving occupational and physical therapy.<br><h3> identification of pathogenic variants<br></h3><br>the subject underwent a basic metabolic evaluation that did not reveal a diagnosis. . wes identified compound heterozygous variants in : c.2215c&gt;t, p. arg739cys and c.1667t&gt;c, p. phe556ser (nm_002161) with a low mean allele frequency in the exac database of 60,000 exomes (2.47 and 0, respectively). the unaffected sisters did not carry these variants (fig. a). complementation studies in yeast demonstrated the variants cause a lossoffunction effect on yeast viability (fig. ). growth associated with the p. phe556ser variant was only visible after 4 days of incubation at 30c, while growth associated with wildtype was visible after 2 days of incubation. furthermore, the number and size of colonies associated with p. phe556ser iars were visibly reduced even after 4 days of incubation. this indicates that p. f556s has impaired function and is thus a hypomorphic allele. the p. arg739cys variant was unable to support any yeast cell growth at both 2 and 4 days of incubation consistent with p. arg739cys resulting in a functional null allele.<br><h2> discussion</h2><br>this report supports the association between biallelic pathogenic variants in and a distinct syndrome characterized by intrauterinegrowth delay, liver dysfunction <span style="color:red" title="HPO: HP:0001410
CONF: 1" >,</span>  and neurodevelopmental disabilities. significant growth delay is a consistent finding in all the reported  <span style="color:red" title="HPO: HP:0001507
CONF: 1" >subjects as well as the potentially equivalent disorder seen in cattle</span>  <span style="color:red" title="HPO: HP:0001510
CONF: 1" > .</span>  the cause for growth delay is unknown and <span style="color:red" title="HPO: HP:0001510
CONF: 1" ></span>  might improve with age and / or gh therapy. one subject was reported to have gh deficiency, however, here we report gh resistance. liver dysfunction and <span style="color:red" title="HPO: HP:0001410
CONF: 1" ></span>  abnormal liver pathology was seen in two previously reported patients and <span style="color:red" title="HPO: HP:0001392
CONF: 1" ></span>  only one presented with neonatal cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >.</span>  that individual also carried a variant of uncertain significance in (mim:603201). the subject reported here had a similar presentation with neonatal liver failure and <span style="color:red" title="HPO: HP:0001399
CONF: 1" ></span>  cholestasis <span style="color:red" title="HPO: HP:0001396
CONF: 1" >.</span>  we did not identify any rare variants in genes related to neonatal cholestasis, supporting the role of in this presentation. here, the liver biopsy was performed at the age of 1 month compared to 12 years in previously reported cases. interestingly, portal tract fibrosis and <span style="color:red" title="HPO: HP:0006580
CONF: 1" ></span>  bile ductular proliferation (positive ck19) was already observed. steatosis was not seen and might be a late manifestation. there was bile ducts paucity which  <span style="color:red" title="HPO: HP:0005248
CONF: 1" >is seen in very few conditions such </span>  <span style="color:red" title="HPO: HP:0030151
CONF: 1" >as congenital sclerosing cholangitis</span>  <span style="color:red" title="HPO: HP:0030991
CONF: 1" >,</span>  alagille syndrome (mim: 118450), drug induced liver injury and the vanishing bile duct syndrome. here, we add an additional condition that may present this way and also associated with immunostain positive for cholangiolar proliferation. in contrast to the previously reported cases, development was normal up to the age of 3 years. at 4 years there is evidence of mild develo <span style="color:red" title="HPO: HP:0001263
CONF: 1" >pmental delay based on cat/clams scores but</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" ></span>  he attends a regular preschool. this supports a variable neurodevelopmental  <span style="color:red" title="HPO: HP:0000707
CONF: 1" >outcome in individuals with this disorder and</span>  <span style="color:red" title="HPO: HP:0012759
CONF: 1" ></span>  potentially typical development and iq in some of the cases. this may depend on the severity of the variants and enzyme residual activity. recurrent infections <span style="color:red" title="HPO: HP:0002719
CONF: 1" >,</span>  low zinc levels and clinical improvement with zinc supplements were reported in the previous cases. however, in this case zinc levels were normal on repeated tests and there was a single bacterial infection. interestingly, 25hydroxy vitamin d levels were high in spite of liver failure <span style="color:red" title="HPO: HP:0001399
CONF: 1" >,</span>  however the levels decreased after discontinuation of routine supplements and the etiology is not clear. on physical exam there was a strikingly round face compared to trunk <span style="color:red" title="HPO: HP:0000311
CONF: 1" >,</span>  increased fat in the genitalia area, as well as soft, translucent and hyperelastic  <span style="color:red" title="HPO: HP:0000973
CONF: 1" >skin with joi</span>  <span style="color:red" title="HPO: HP:0000974
CONF: 1" >nt laxity (fi</span>  <span style="color:red" title="HPO: HP:0001388
CONF: 1" >g.</span>  b). these findings may have been overlooked previously, or more prominent at an younger age. reports on additional individuals with this condition will help determine whether this is a common feature that may assist in clinical diagnosis and point to a role of in connective tissue development.<br>the subject had two novel variants intrans. the variants were located within the catalytic and anticodon recognition domains and are conserved down to yeast (fig. c,d). the c.2215c&gt;t, p. arg739cys variant is in a previously described trna binding site and the c.1667t&gt;c, p. phe556ser variant is four residues upstream of a catalytic active site . we performed complementation studies in yeast using the human gene. the variants assessed affected yeast viability to a varying extent. the p. phe556ser variant had impaired function but did enable growth, however p. arg739cys was unable to support any yeast cell growth (fig. ). therefore, similar to the previously reported cases, the proband has one null allele and one hypomorphic allele. there are currently no reports of individuals with two null alleles, potentially because these will result in early lethality. similarly, there are no reports on two hypomorphic alleles (compound heterozygous or homozygous). it is possible that such individuals will have a milder and less recognizable phenotype.<br>in summary, this report supports the association between biallelic pathogenic variants in and intrauterine growth delay and <span style="color:red" title="HPO: HP:0001510
CONF: 1" ></span>  liver dysfunction wit <span style="color:red" title="HPO: HP:0001396
CONF: 1" >h neonatal cholestasis</span>  <span style="color:red" title="HPO: HP:0001410
CONF: 1" >.</span>  we expand the phenotype to in <span style="color:red" title="HPO: HP:0001263
CONF: 1" >clude mild developmental delay</span>  <span style="color:red" title="HPO: HP:0012825
CONF: 1" >,</span>  skin and joint laxity and <span style="color:red" title="HPO: HP:0001388
CONF: 1" ></span>  hypervitaminosis d. further reports on individuals with this condition will help define the clinical spectrum.<br><h2> acknowledgements</h2><br>we are thankful to the family for consenting to participate in this publication. the pyy1 expression construct was a gift from chinl chien and chienchia wang (national central university, taiwan). a. a. is supported by a grant from the national institute of general medical sciences (gm118647). the nih intramural sequencing center (nisc) conducted thesequencing experiments in this project. this work was supported by the intramural program of the national human genome research institute, nih.<br><h2></h2><br>filename<br>description<br>jpeg image, 84.8 kb<br>fig. s1 vitamin d levels. 25hydroxy vitamin d levels were elevated on a few measurements and decreased after routine vitamin d supplements (400 u daily) were discontinued at 12 months.<br>word 2007 document <span style="color:red" title="HPO: HP:0100512
CONF: 1" ><br>,</span>  14.1 kb<br>appendix s1. methods.<br>please note: the publisher is not responsible for the content or functionality of any supporting information supplied by the authors. any queries (other than missing content) should be directed to the corresponding author for the article.<br><h2><br>references<br></h2><br><h2>citing literature</h2><h3>number of times cited according to crossref: 8</h3><br>june 2017<br>pages 913-917<br><h5><br><h2><br>additional links<br></h2><br><h3>about wiley online library</h3><br><h3>help &amp; support</h3><br><h3>opportunities</h3><br><h3>connect with wiley</h3><br>copyright 1999-2020 . all rights reserved<br>the full text of this article hosted at iucr.org is unavailable due to technical difficulties.<br><h5><br><h5><br><h2>log in to wiley online library</h2><br>email or customer id<br>password<br><h5><br><h5><br><h2>change password</h2><br>old password<br>new password<br>too short<br>weak<br>medium<br>strong<br>very strong<br>too long<br><h2>password changed successfully</h2><br>your password has been changed<br><h5><br><h2>create a new account</h2><br>email or customer id<br><h5><br><br><h5><br><h2>forgot your password?</h2><br>enter your email address below.<br>email or customer id<br>please check your email for instructions on resetting your password.<br>if you do not receive an email within 10 minutes, your email address may not be registered,<br>and you may need to create a new wiley online library account.<br><h2>request username</h2><br><br>can't sign in? forgot your username?<br><br>enter your email address below and we will send you your username<br>email or customer id<br>if the address matches an existing account you will receive an email with instructions to retrieve your username<br>